絞り込み

16638

広告

Attitudes toward clinical trials across the Alzheimer's disease spectrum.

著者 Nuño MM , Gillen DL , Dosanjh KK , Brook J , Elashoff D , Ringman JM , Grill JD
Alzheimers Res Ther.2017 Oct 04 ; 9(1):81.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (3view , 0users)

Full Text Sources

Medical

Research has revealed that manifest Alzheimer's disease (AD) dementia is preceded by preclinical and prodromal phases during which pathology is accumulating but function remains intact. This understanding and concern that disease-modifying interventions initiated at the dementia stage may come too late in the neurodegenerative process to be successful has led to a paradigm shift in AD clinical trials. AD trials now enroll patients with mild cognitive impairment (MCI) and persons with no cognitive symptoms. Trial designs are similar to those enrolling dementia participants. We set out to test the hypothesis that attitudes towards trial design features differ among different potential AD trial populations.
PMID: 28978335 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード